Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.

Abstract

Recent systemic treatment advances have transformed hepatocellular carcinoma (HCC) management, particularly with immunotherapy's superior outcomes over tyrosine kinase inhibitors, as demonstrated in trials like HIMALAYA, CheckMate 9DW and Imbrave-150. Atezolizumab and bevacizumab (AtezoBev) are now standard first-line treatments for advanced HCC. However, they present a risk of adverse events (AEs) that require careful monitoring, especially in patients with advanced chronic liver disease and related complications. This study investigates bevacizumab-related complications (B-AEs) in this population, emphasizing the importance of rigorous patient selection and management in achieving successful outcomes.